1. FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.; Hartung, H.P.; Kappos, L.; Montalban, X.; Hughes, R.; Koendgen, H.; McNamara, J.; Pradhan, A.; Wormser, D.; Wolinsky, J.S. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1477: CHARACTERIZING SICKLE CELL DISEASE AND BURDEN OF ILLNESS IN THE UNITED STATES OF AMERICA: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA. (23rd June 2022) Authors: Clay, E. L. J.; Paulose, J.; Rowe, C.; Tierney, M.; Zhou, Y.; Pattipaka, T.; Wormser, D.; Fermont, J. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P23 Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany – CONFIDENCE Baseline Characteristics. Issue 4 (April 2020) Authors: van Hall, V.; Hartung, H.P.; Dirks, P.; Eggebrecht, J.; Hieke-Schulz, S.; Leemhuis, J.; Wormser, D.; Ziemssen, T. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗